EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

External validation of MAGIC-D model in Taiwanese patients with advanced biliary tract cancer receiving durvalumab and chemotherapy

Chung-Hao Ku, Wen-Kuan Huang, Chun-Feng Wu, Chun-Yi Tsai, Jun-Te Hsu, Shao-Ming Yu, Ming-Mo Hou, Po-Jung Su, Chi-Chen Lan, Chi-Lin Hsieh, Yu-Wei Hsu, Jen-Shi Chen und 3 weitere

Biomedical Journal · 2026-12 · 49 (6) · 100995

DOI: 10.1016/j.bj.2026.100995 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Biomedical Journal, 2026-12. Verfasst von Chung-Hao Ku und 14 weiteren Autor:innen. Beteiligte Einrichtung: Department of Hematology and Oncology, Chang Gung Memorial Hospital at Linkou, Taoyuan, Taiwan; College of Medicine, Chang Gung University, Taoyuan, …. Die Arbeit nennt 28 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Chang Gung Memorial Hospital.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: The MAGIC-D score is a prognostic index developed to stratify outcomes in patients with advanced biliary tract cancer (BTC) treated with gemcitabine-cisplatin-durvalumab (GCD). We conducted an external validation study to evaluate the prognostic performance of MAGIC-D in a real-world Taiwanese cohort. MATERIAL AND METHODS: We reviewed patients with unresectable or metastatic BTC receiving first-line GCD at four centers between 2021 and 2025. Baseline clinical, laboratory, treatment, and safety data were collected. Patients were classified into low-, intermediate-, and high-risk groups using MAGIC-D. Overall survival (OS) and progression-free survival (PFS) were estimated using Kaplan-Meier analysis with hazard ratios (HRs) from Cox regression. Model discrimination was assessed using area under the curve (AUC). RESULTS: Of 172 patients, MAGIC-D classified 48 (27.9%) as low-risk, 80 (46.5%) intermediate-risk, and 44 (25.6%) as high-risk. Median OS and PFS were 13.8 and 5.1 months, respectively for the entire cohort. Median OS by risk group was 23.2 months (low), 16.3 months (intermediate; HR 1.95, 95% CI 1.04-3.67), and 4.9 months (high; HR 7.12, 95% CI 3.70-13.7). PFS times were 6.7, 5.1, and 2.2 months, respectively. MAGIC-D achieved AUCs of 0.755 and 0.749 for 6- and 12-months survival prediction, respectively, outperforming neutrophil-to-lymphocyte ratio and other baseline factors. CONCLUSION: In this first external validation in Asian BTC patients, MAGIC-D effectively stratified patients by survival and treatment response. MAGIC-D may aid in risk-adapted patient counseling, follow-up planning, and clinical trial stratification for GCD-treated BTC.

Schlagwörter

Stichwörter der Autor:innen

CholangiocarcinomaImmunotherapyPrognosisRisk

Autor:innen und Institutionen

  • Department of Hematology and Oncology, Chang Gung Memorial Hospital at Linkou, Taoyuan, Taiwan; College of Medicine, Chang Gung University, Taoyuan, Taiwan.
  • Department of Hematology and Oncology, Chang Gung Memorial Hospital at Keelung, Keelung, Taiwan; College of Medicine, Chang Gung University, Taoyuan, Taiwan.
  • Department of General Surgery, Chang Gung Memorial Hospital at Linkou, Taoyuan, Taiwan; College of Medicine, Chang Gung University, Taoyuan, Taiwan.
  • Department of Hematology and Oncology, New Taipei Municipal TuCheng Hospital, New Taipei City, Taiwan; College of Medicine, Chang Gung University, Taoyuan, Taiwan.
  • Department of Hematology and Oncology, Chang Gung Memorial Hospital at Linkou, Taoyuan, Taiwan; College of Medicine, Chang Gung University, Taoyuan, Taiwan. Electronic address: wenchi3992@yahoo.com.tw.

Förderung

  • Chang Gung Memorial Hospital

Zitieren

APA

Ku, C. H., Huang, W. K., Wu, C. F., Tsai, C. Y., Hsu, J. T., Yu, S. M., Hou, M. M., Su, P. J., Lan, C. C., Hsieh, C. L., Hsu, Y. W., Chen, J. S., Hsieh, C. H., Hung, Y. S., & Chou, W. C. (2026). External validation of MAGIC-D model in Taiwanese patients with advanced biliary tract cancer receiving durvalumab and chemotherapy. Biomedical Journal, 49(6), 100995. https://doi.org/10.1016/j.bj.2026.100995

Vancouver

Ku CH, Huang WK, Wu CF, Tsai CY, Hsu JT, Yu SM, et al. External validation of MAGIC-D model in Taiwanese patients with advanced biliary tract cancer receiving durvalumab and chemotherapy. Biomedical Journal. 2026;49(6):100995. doi:10.1016/j.bj.2026.100995

BibTeX
@article{Ku2026,
  author = {Ku, Chung-Hao and Huang, Wen-Kuan and Wu, Chun-Feng and Tsai, Chun-Yi and Hsu, Jun-Te and Yu, Shao-Ming and Hou, Ming-Mo and Su, Po-Jung and Lan, Chi-Chen and Hsieh, Chi-Lin and Hsu, Yu-Wei and Chen, Jen-Shi and Hsieh, Chia-Hsun and Hung, Yu-Shin and Chou, Wen-Chi},
  title = {External validation of MAGIC-D model in Taiwanese patients with advanced biliary tract cancer receiving durvalumab and chemotherapy},
  journal = {Biomedical Journal},
  year = {2026},
  volume = {49},
  number = {6},
  pages = {100995},
  doi = {10.1016/j.bj.2026.100995}
}
Kostenlos starten →